- Home
- BCLI vs MYNZ Comparison
BCLI vs MYNZ Comparison
Compare BCLI & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCLI
- MYNZ
- Stock Information
- Founded
- BCLI 2000
- MYNZ 2021
- Country
- BCLI United States
- MYNZ Germany
- Employees
- BCLI N/A
- MYNZ N/A
- Industry
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- BCLI Health Care
- MYNZ Health Care
- Exchange
- BCLI Nasdaq
- MYNZ Nasdaq
- Market Cap
- BCLI 6.4M
- MYNZ 7.2M
- IPO Year
- BCLI N/A
- MYNZ 2021
- Fundamental
- Price
- BCLI $0.92
- MYNZ $3.20
- Analyst Decision
- BCLI Strong Buy
- MYNZ Buy
- Analyst Count
- BCLI 1
- MYNZ 2
- Target Price
- BCLI $30.00
- MYNZ $14.00
- AVG Volume (30 Days)
- BCLI 366.6K
- MYNZ 105.1K
- Earning Date
- BCLI 05-13-2025
- MYNZ 05-06-2025
- Dividend Yield
- BCLI N/A
- MYNZ N/A
- EPS Growth
- BCLI N/A
- MYNZ N/A
- EPS
- BCLI N/A
- MYNZ N/A
- Revenue
- BCLI N/A
- MYNZ $893,991.00
- Revenue This Year
- BCLI N/A
- MYNZ $42.95
- Revenue Next Year
- BCLI N/A
- MYNZ N/A
- P/E Ratio
- BCLI N/A
- MYNZ N/A
- Revenue Growth
- BCLI N/A
- MYNZ N/A
- 52 Week Low
- BCLI $0.72
- MYNZ $0.18
- 52 Week High
- BCLI $10.05
- MYNZ $8.20
- Technical
- Relative Strength Index (RSI)
- BCLI 35.85
- MYNZ 40.90
- Support Level
- BCLI $1.12
- MYNZ $3.03
- Resistance Level
- BCLI $0.82
- MYNZ $3.31
- Average True Range (ATR)
- BCLI 0.12
- MYNZ 0.35
- MACD
- BCLI 0.01
- MYNZ 0.06
- Stochastic Oscillator
- BCLI 36.36
- MYNZ 61.80
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.